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Abstract
Transmission-blocking vaccines (TBVs) utilize Plasmodium sexual stage proteins to induce
antibodies that prevent parasites from infecting blood-fed mosquitoes. This type of vac-
cine, which can be considered a “vaccine of solidarity,” reduces Plasmodium infections
within communities without conferring direct protective immunity to the vaccine recipi-
ents. The leading TBV candidates have advanced to field clinical trials, where vaccine-
induced antibody function has been demonstrated in mosquito-feeding assays. However,
the duration of functional antibody responses has been short-lived; hence current devel-
opment has focused on improved adjuvant and vaccine delivery systems to generate long-
lasting immune responses. For the future implementation of TBVs, community percep-
tions and understandings should be considered, and education should be provided on the
concept and its value. Implementation will need to be undertaken in harmony with
current malaria control policies.
Keywords: transmission-blocking vaccine, malaria, mosquito-feeding assays, elimination,
eradication
1. Introduction
Malaria elimination and eradication have received renewed attention as the best long-term
solution to this ancient scourge. However, existing tools that have been programmatically
implemented have been insufficient to achieve elimination in areas of Africa, as well as at a
global scale. Thus, new products are needed to pursue elimination, and efficacious vaccines
are generally conceded to be ideal population-based interventions to support disease eradica-
tion. In this chapter, we describe the rationale and status of transmission-blocking vaccines
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
(TBV), which will contribute to malaria elimination and eradication. We place TBV in the
context of overall malaria vaccine development and highlight the role and challenges of TBV
field trials, which are needed to confirm activity and guide implementation.
2. Current malaria burden and need for elimination/eradication
Malaria is the most important parasitic disease and is endemic across the globe, most impor-
tantly sub-Saharan Africa, South and Southeast Asia, Papua New Guinea, and South America.
Its burden remains unacceptably high, especially in sub-Saharan Africa, despite the significant
gains with the use of current tools including vector control, diagnostics, chemoprevention and
treatment. In 2016, 216 million malaria cases and 445,000 deaths were recorded worldwide
mostly caused by Plasmodium falciparum, 90% of which occurred in sub-Saharan Africa [1].
Since artemisinins constitute the core component of the current malaria treatments, the recent
emergence of artemisinin resistance in Southeast Asia [2–4] has become a serious obstacle for
the malaria elimination agenda. Although the current phenotypes of artemisinin resistance are
limited to slow parasite clearance and parasite recrudescence, their impact in malaria-endemic
areas could result in a considerable increase of malaria cases, deaths, and economic costs
according to predictive models [5, 6]. Indeed, the probable spread of artemisinin resistance to
sub-Saharan Africa, where the burden of malaria is the highest, could jeopardize the lives of
millions of children. Furthermore, the spread of insecticide and mosquito behavioral resistance
compromises malaria control via the failure of vector control interventions such as indoor
residual spraying (IRS) and insecticide-treated nets (ITN). Given that current strategies will
eventually fail, new tools are urgently needed for malaria control and treatment. To overcome
these constraints, transmission-blocking vaccines (TBVs) offer a new approach by targeting
developing parasites in the mosquito host (a bottleneck in the malaria parasite lifecycle) and
thereby contributing to malaria elimination and potentially eradication.
3. Need for malaria vaccine strategy
Vaccines are powerful tools that could accelerate malaria elimination efforts. Historically,
vaccine-based strategies have contributed to the successful eradication of infectious diseases
in humans and animals, including smallpox and rinderpest [7, 8]. Poliomyelitis is now close to
eradication through routine Expanded Programme on Immunization (EPI) and massive
immunization campaigns in some areas. Vaccination is a safe and cost-effective strategy that
is easily implemented in large populations to reduce or even eliminate disease morbidity and
mortality. Vaccine-induced immune responses protect individuals against infection or disease
and can also stop transmission of the causative agent. With high coverage, vaccines protect not
only recipients but also non-immunized individuals within the population through the effect
of herd immunity. Malaria vaccines, even those with modest efficacy, such as the RTS,S
product (see below in “Current status of malaria vaccine research”), are expected to avert
millions of clinical malaria cases and thousands of severe malaria cases, hospitalizations, and
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deaths, according to prevalence-based predictive models [9–11]. The complex malaria parasite
lifecycle (Figure 1) offers several stages that can be targeted by various vaccine strategies,
which in combination may interrupt transmission.
4. Benefits of malaria transmission-blocking vaccines
Current malaria vaccine approaches target various parasite lifecycle stages including liver and
blood stages in the individual and sexual stages in the mosquito (Figure 1). Liver stage
vaccines, best typified by whole sporozoite (SPZ) vaccines that induce sterile protection [12],
presumably act through T cell responses [13] and possibly antibodies and prevent progression
of liver stage infections to blood stage parasitemia. Blood stage vaccines on the other hand
Figure 1. Malaria parasite life cycle and vaccine targets. Transmission-blocking vaccines are directed against the
sexual stages of malaria parasite development in the mosquito, while other stages of the parasite life cycle can be
targeted with different vaccine approaches. The vaccine concepts, candidate vaccines, and candidate antigens
discussed in this chapter are presented according to their targeted stage of the parasite life cycle, as well as their
anticipated biological effects: transmission-blocking, anti-infection, and anti-disease effects. Illustration by Alan
Hoofring, Medical Arts Design Section, NIH.
Malaria Transmission-Blocking Vaccines: Present Status and Future Perspectives
http://dx.doi.org/10.5772/intechopen.77241
365
confer protection that reduces malaria episodes, disease severity, and/or parasitemia. Addi-
tionally, immunity against VAR2CSA, a member of the P. falciparum erythrocyte membrane
protein 1 family that binds to chondroitin sulfate A, may prevent placental malaria [14].
Vaccines that target the sexual stages, known as TBVs, are the focus of this chapter. TBVs do
not directly protect immunized individuals but specifically block onward transmission by
preventing mosquito infection. TBVs utilize antigens expressed during mosquito parasite
stages (gametocytes, gametes, zygotes and ookinetes) to induce functional antibodies that
attack the parasite in the mosquito and impair its viability, inhibit its development, or impede
its interaction with the mosquito midgut. The effector antibody responses involved in these
types of vaccines include neutralization and complement-mediated lysis. A broader concept
coined as a Vaccine to Interrupt Malaria Transmission (VIMT) by the Malaria Eradication
Research Agenda (MalERA) includes not only TBVs but also pre-erythrocytic and blood stage
vaccines, as well as mosquito molecules involved in parasite development [15] such as Anoph-
eles gambiae aminopeptidase 1 (AnAPN1), carboxypeptidase, and saglin.
Ideally, TBVs will elicit effective antibodies that prevent malaria parasite development in
mosquitoes after uptake of blood meals. This will reduce the number of circulating infectious
mosquitoes below a threshold that sustains transmission. TBVs are among the tools being
encouraged for use during pre-elimination and elimination phases of malaria eradication
according to malERA [15] and could be an effective alternative or adjunct to vector control.
Compared to vector control interventions, TBVs are ecologically safer, cost-effective, and
readily enable high coverage of populations.
Most TBV antigens are genetically conserved, which may be due to limited immune pressure.
The effect of immune pressure exerted by TBV against the parasite remains unknown and will
need to be monitored in future. Notably, sexual stages are critical for the generation of parasite
genetic diversity and regulation of parasite virulence, hence the effects of TBVs on these
phenomena also warrant monitoring. In addition, malaria parasites experience a considerable
population bottleneck in the mosquito for only a handful of parasite zygotes progressing to
oocysts on the mosquito midgut. Altogether, while these observations make the mosquito
phase an attractive target for vaccine development, much remains to be done to achieve
implementable and effective TBVs.
5. Current status of malaria vaccine research
The development of effective vaccines against eukaryotic organisms is far from easy and has
been particularly difficult for P. falciparum, a protozoan parasite characterized by three
genomes (nuclear, mitochondrial, and apicoplastid), an adenine-thymine rich (~80%) nuclear
genome [16] encoding >5000 genes, and a complex lifecycle involving several developmental
stages between vertebrate and invertebrate hosts. Malaria vaccine development has been
hampered by several factors during a century of effort, including the genetic diversity of
P. falciparum, complexity of its biology, and difficulty obtaining long-lasting effective immunity.
Interestingly, adults living in hyperendemic settings are continuously exposed to infective
Towards Malaria Elimination - A Leap Forward366
mosquito bites and naturally acquire immunity that controls parasitemia and reduces clinical
episodes of malaria over time. Responses against some parasite proteins have been associated
with this natural protection, which makes them promising vaccine targets [17].
Today, the most advanced malaria vaccine is RTS,S, a pre-erythrocytic stage vaccine consisting
of a virus-like particle (VLP) that displays hepatitis B surface antigen alone (S) and fused with
a P. falciparum circumsporozoite protein fragment containing its central repeats and T cell
epitopes (RTS). RTS,S has completed Phase III clinical trial (vaccine given to thousands of
people and tested for efficacy and safety) and showed an efficacy of 51.3% (95%CI, 47.5–54.9)
against clinical malaria in 5- to 17-month children over 12 months after three doses of the
vaccine. A fourth dose was required to sustain protection over longer periods [18]. RTS,S is
currently in pilot implementation studies involving 360,000 young children, expected to be
given the vaccine in Ghana, Kenya, and Malawi. Although this represents important progress
given the absence of any other human vaccine against a eukaryotic pathogen, more research is
needed to develop vaccines that meet the Malaria Vaccine Technology Roadmap goals of 50%
efficacy against severe malaria for more than one year and ≥75% long lasting efficacy against
clinical malaria. For example, alternative dosages, timing and number of doses, are being
evaluated as strategies to improve RTS,S efficacy [19, 20].
Attenuated whole SPZ vaccines have shown high-level sterile protection (>90%) against
homologous challenge in early clinical trials [21] and thus have been heralded as a promising
malaria vaccine approach. The concept of immunization using the whole SPZ was first
attempted in 1910 by the French scientist Sergent using an avian model of malaria [22]. Several
decades later, protective immunity was induced in mice following inoculation of X-irradiated
SPZ of P. berghei [12]. In 1973, this approach was shown to be protective in humans, using X-
irradiated SPZ of P. falciparum to vaccinate, followed by challenge with the non-irradiated
homologous strain delivered by mosquito bites [23]. More recently, inoculation of non-
attenuated fully infectious SPZ from chemo-sensitive strains along with administration of
effective antimalarial drugs, known as chemoprophylaxis vaccination, was shown to induce
sterilizing immunity [24]. Immunity induced by chemoprophylaxis vaccination is dose-
dependent and requires substantially smaller SPZ inocula compared to irradiated SPZ [25].
Finally, genetic attenuation of parasites through the deletion of liver developmental stage-
specific genes by homologous recombination is also being pursued to generate whole SPZ
vaccines [26]. Numerous technologies may generate genetically attenuated parasite vaccines,
including flippase (Flp)/Flp recognition target, Cre/loxP recombination, zing-finger nucleases,
and the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-
associated protein 9 (CRISPR/Cas9) system [27–30]. Genetic attenuation enables generation of
parasites that arrest at late liver stages, exposing a broader liver stage-specific antigen reper-
toire to the immune system over a longer duration. However, genetic attenuation can be
incompletely effective for preventing breakthrough to blood stage parasitemia, and this needs
to be monitored carefully in clinical studies. Further, the requirement for mosquitoes to deliver
SPZ vaccines had been considered as an insuperable obstacle to development of a whole SPZ
vaccine for mass immunization. This obstacle has been partially overcome by the production
of purified, aseptic, and cryopreserved SPZ for syringe injection by Sanaria Inc. [31].
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The blood stage is another important focus for malaria vaccine research, as this stage is
responsible for the clinical manifestations of malaria. People living in endemic areas are
repeatedly exposed to blood stage parasites and acquire protective antibodies over years that
control parasitemia and prevent disease; consequently, a blood stage vaccine can be composed
of antigens targeted by naturally acquired immunity that prevent clinical episodes of malaria
[17, 32]. For example, immune responses to combinations of merozoite antigens were associ-
ated with 100% protection against clinical episodes of malaria in Kenyan observational cohorts
[17]. Unfortunately, the efficacy of merozoite antigen vaccines in interventional trials has been
poor, limited in part by antigenic diversity, which must be overcome for effective strain-
transcending vaccines [33, 34].
6. Transmission-blocking vaccine (TBV) development
The first demonstration of antibodies that prevented mosquito infection was reported in 1958
using the avian species Plasmodium gallinaceum [35]. However, it remained until 1976 for
studies to show that such antibodies might recognize gamete proteins and therefore act against
the parasite in the invertebrate rather than vertebrate host [36, 37]. These gamete proteins were
subsequently characterized to be P230 and P48/45, and later the zygote/ookinete surface pro-
teins P28 and P25 were shown to be TBV targets; “P” refers to Plasmodium (the antigens have
homologs in all Plasmodium species to date), and the number refers to their molecular weights
on SDS-PAGE [38, 39]. P28 and P25 are paralogs, most abundant on the surface of zygotes and
ookinetes, glycosylphosphatidylinositol (GPI)-anchored, and involved in ookinete formation.
Today, these four parasite proteins represent the leading TBV candidates. Ookinete-secreted
proteins have also been identified as targets for TBVs, including chitinase 1, von Willebrand
factor-A domain-related protein, thrombospondin-related anonymous protein-related protein,
membrane-attack ookinete protein, secreted ookinete adhesive protein (SOAP), and cell-
traversal protein for ookinetes and sporozoites (CelTOS) [40, 41].
TBVs that have reached human clinical trials include only Pfs25 and its Plasmodium vivax
ortholog Pvs25, and Pfs230. Early clinical trials of Pfs25 and Pvs25 yielded poor results due to
either poor production of antibodies with transmission-blocking activity or to significant
reactogenicity attributed to adjuvant formulations [42–44]. These challenges have been
addressed by advances in vaccine expression systems, delivery platforms, and adjuvant for-
mulations. Production of recombinant TBV antigen has been assessed in numerous systems,
including Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, and baculovirus/insect cells,
to yield better-folded proteins that are stable in solution and recreate conformational epitopes.
Pfs230 and Pfs45/48 vaccines in particular are hampered by difficulty in expressing them in
their appropriate conformations. To overcome this, research has focused on the expression of
immunogenic fragments rather than full-length proteins [45, 46].
Several approaches to vaccine particle preparation have also been pursued to increase immu-
nogenicity. These include conjugation to carriers (such as Pseudomonas aeruginosa exoprotein A
(EPA) [47] and bacterial outer membrane protein complex (OMPC) [48]) or fusion to partners
that complex to generate particles (such as C4 bp oligomerization domain (IMX313) expressed
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in E. coli [49, 50] or modified lichenase carrier (LiKM) produced in Nicotiana benthamiana [50]).
Viral vector vaccines, such as Chad63/Modified Vaccinia Ankara, are also being assessed to
improve immunogenicity [49].
Adjuvants, such as Alhydrogel® and Montanide®, have been used for clinical trials of TBVs
with reactogenicity issues observed with both; however, recent trials of Alhydrogel®-formu-
lated TBV have demonstrated good safety and reactogenicity profiles. Recently, GSK®’s lipo-
somal adjuvant AS01 has been considered for TBVs. AS01 incorporates the TLR4 ligand MPL
and the saponin derivative QS-21, and because AS01 is used for formulating the pre-
erythrocytic vaccine RTS,S, this would simplify future efforts to combine products.
TBV candidates that are in clinical and preclinical developments are summarized in Table 1.
Human studies of Pfs25 and Pvs25 showed that priming doses of the vaccines do not induce
detectable antibody levels [42, 51]. Antibody production is measurable after the first boost and
then rapidly declines; additional boosts are required to retain antibody titers. However, the
raised antibodies have been proven to be functional, i.e. capable of reducing oocyst formation
in mosquito-feeding assays, and this activity strongly correlates to antibody titer [42, 51]. In
addition to Pfs25/Pvs25 candidates, Pfs230 conjugated to EPA and adjuvanted in Alhydrogel®
or AS01 has advanced to clinical trials for evaluation either alone or in coadministration with
Pfs25 (https://clinicaltrials.gov/, trials NCT02334462 and NCT02942277).
Vaccine candidate Type Stage of
development




Subunit vaccine Phase 1 NCT02942277
Pfs230D1M-EPA/Alhydrogel® and/or Pfs25
EPA/Alhydrogel®
Subunit vaccine Phase 1 NCT02334462
Pfs25-EPA/Alhydrogel® Subunit vaccine Phase 1 NCT01867463, 51






Pfs25 & Pvs25/Montanide ISA 51 Subunit vaccine Phase 1 [43]
Pvs25H/Alhydrogel® Subunit vaccine Phase 1 [42]
Pfs25-Pfs25 Conjugate vaccine Phase 1 NCT00977899
Plant-Produced Pfs230 LiKM Subunit vaccine Preclinical [57]
Pfs48/45 Subunit vaccine Preclinical [58, 59]
Pvs48/45 DNA vaccine Preclinical [60]
Pvs47 DNA vaccine Preclinical [60]
Pfs28 Subunit vaccine Preclinical [61, 62]
PfHAP2 Subunit or viral vector
vaccine
Preclinical [55, 63]
AnAPN1 Subunit vaccine Preclinical [59, 64]
Table 1. Transmission-blocking vaccine (TBV) candidates in clinical and preclinical developments.
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7. Field studies of TBVs and Malian experiences
Field clinical trials are a major component of TBV development. TBV candidates are generally
discovered in laboratories in the North with extensive infrastructure for modern biological
sciences to conduct discovery research. After passing preclinical evaluations, TBV candidates
must be tested in humans to qualify as viable vaccines. Safety and tolerability of the products
are assessed first, generally in malaria-naïve individuals in non-endemic countries during a
first-in-human phase 1 study. If the product meets acceptable safety and tolerability criteria,
then it advances to Phases I, II, and III field clinical trials, which often means evaluation in
malaria-endemic settings. Field studies are essential for assessing interruption of malaria
transmission in the communities living in malaria-endemic areas.
A field clinical trial is not just a simple study but rather a multifaceted activity that builds on
strong partnerships between research institutions and affected communities. Various capabil-
ities are required for successful clinical trials, including confidence-based collaborative
research teams, facilities, equipment, written procedures, training programs, community
engagement, collaboration with ethics review committees, and collaborations with health and
political authorities. The partnerships include vaccine inventors, developers, sponsors/funders,
and institutions that have appropriate capacities and experience in conducting field clinical
trials of malaria vaccines.
The main components of a TBV field clinical trial comprise immunization of study volunteers
with prime and boost doses, intensive safety follow-up and reporting, mosquito-feeding
assays, and the measurement of antibody responses using enzyme-linked immunosorbent
assay (ELISA) for titers and standard membrane-feeding assay (SMFA) for activity. The immu-
nization of volunteers is a major event that involves professionals with sundry expertise. The
professionals include clinicians who assess volunteers for inclusion/exclusion criteria and
monitor their health after receiving the vaccination, pharmacists who manage the randomiza-
tion list as well as vaccine preparation, physicians who administer the vaccines, and
intensivists who provide care for any post-immunization emergency. Medical biologists ensure
proper biological sample collection, processing, transport, and storage as well as immediate
measurement of biological parameters. Medical entomologists perform mosquito-feeding
assays and associated dissections for endpoint analysis, and data managers enter and ensure
quality of data according to established procedures.
8. Measuring vaccine activity
Unlike other vaccines where controlled human malaria infection (CHMI) studies are useful for
assessing efficacy, field assessment of TBV efficacy currently requires mosquito-feeding assays
on individuals living in malaria-endemic areas. Several mosquito-feeding assays can be uti-
lized to assess the capacity of vaccine-induced antibodies to interfere with mosquito infectivity
including direct skin-feeding (DSF) assay, direct membrane-feeding assay (DMFA), and stan-
dard membrane-feeding assay (SMFA). The DMFA entails feeding of laboratory-reared
uninfected mosquitoes on venous blood immediately after collection from study participants
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(Figure 2A). Feeding occurs through various types of membranes, such as pig intestine or
Parafilm®, to access infected blood housed in a heated chamber that attracts mosquitoes. This
method takes the diversity of infection in the population into account. The standard
membrane-feeding assay (SMFA) is the gold-standard technique for functional evaluation of
antibodies in TBV studies, given its use of a well-characterized laboratory parasite isolate and
mosquito line that lend themselves to standardization. Mosquitoes feed on cultured gameto-
cytes together with either volunteer serum or purified immunoglobulin (Figure 2B). SMFA is
similar to DMFA in the machinery and process for feeding but fails to capture parasite
diversity effects on vaccine activity.
In DSF assays, cups of field-adapted, laboratory-reared mosquitoes are fed on the skin of
human volunteers to assess the ability of vaccine antibody responses to block malaria trans-
mission in near-natural conditions (Figure 3). In a recent advance, the Malaria Research and
Training Center (MRTC) in Bamako (Mali) and the Laboratory of Malaria Immunology and
Vaccinology (LMIV) at NIAID/NIH, in Rockville, MD (USA) have established the infrastruc-
ture, logistics, and safety database to support scale up of DSF assays on a community-wide
basis (Figure 3). These DSF assays use a line of locally caught Anopheles coluzzii recently
adapted for breeding in a contained insectary. In these studies [52], uninfected mosquitoes
(generally 30–60 per assay) are fed on study volunteers on a regular basis during the malaria
transmission season, with the expectation that an effective vaccine will reduce the number of
infected mosquitoes compared to controls. We believe DSFs, in which insectary-raised clean
mosquitoes are directly fed on infected individuals, may be more likely to be predictive of an
intervention’s impact on transmission than membrane feeds.
Figure 2. Membrane-feeding assays. (A) Overall setup of a direct membrane-feeding assay (DMFA). DMFA was
performed at the Malaria Research and Training Center (MRTC), Mali with mosquitoes feeding through a membrane on
whole venous blood taken in citrate-phosphate-dextrose or heparin from infected donors. The mosquitoes used were F1
or F2 progeny of wild-caught mosquitoes, or MRTC colony-bred mosquitoes (Anopheles coluzzii) maintained for many
generations after local capture. The gametocyte source was fresh venous blood collected from infected study volunteers in
Mali. (B) Standard membrane-feeding assay (SMFA) showing an individual feeding chamber. SMFA performed at the
Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases
(NIAID)/National Institutes of Health (NIH), Rockville, MD, USA with mosquitoes feeding through a membrane on
laboratory-cultured parasites (gametocytes) suspended in media with immune or nonimmune serum/plasma or IgG.
The mosquitoes used were an established laboratory strain (commonly Anopheles stephensi).
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For all these methods (SMFA, DMFA, DSF), mosquitoes are dissected about a week after
feeding for oocyst detection and counting by microscopy. The results of the mosquito-feeding
assay allow the calculation of transmission-blocking activity and transmission reducing
Figure 3. Direct skin feeds (DSF). DSF was performed at the Malaria Research and Training Center (MRTC), Mali at the
study sites. MRTC colony-bred mosquitoes (Anopheles coluzzii) raised in containment fed directly on skin of consenting
study participants. The gametocyte source was infected study volunteers in Mali. Ethical approvals were obtained from
both the NIAID/NIH IRB (National Institute of Allergy and Infectious Diseases/National Institutes of Health, Rockville,
MD, USA Institutional Review Board) and the Mali FMPOS (Faculty of Medicine, Pharmacy and Odonto-Stomatology)
Ethics Committee.
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activity, which are respectively the ratio of the proportions of infected mosquitoes and the
mean counts of oocysts, between test and control mosquitoes.
The measurement of antibody titers during field clinical trials of TBVs (generally by ELISA) is
required to assess the immunogenicity of vaccine candidates. Samples are assayed to detect any
pre-existing immunity against vaccine candidates, to determine vaccine immunogenicity after
prime and boost doses, and to monitor the decay of antibody titers during the follow-up. In
addition, antibody titer data can be linked with mosquito-feeding assay data to determine the
correlation between antibody production and functionality. Many further investigations can be
performed with samples collected from the study volunteers for other exploratory objectives.
9. The Malaria Research and Training Center (MRTC) field trials
experience
The achievement of all field activities requires an institution endowed with strong capacities
and trained staff. Malaria Research and Training Center (MRTC), founded in 1992 at the
Department of Parasitic Diseases Epidemiology based at the University of Sciences, Tech-
niques and Technologies of Bamako (USTTB) in Mali, is a leading institution in conducting
field clinical trials of TBVs in Africa. The center is the result of a partnership between the
Malian government and US National Institutes of Health (NIH) to build capacity in malaria
research and training in Mali. The USTTB collaboration has been designated by NIH as an
International Center for Excellence in Research (ICER).
MRTC comprises six equipped and autonomous clinical trial sites located in malaria-endemic
Malian villages that fulfill International Conference on Harmonization (ICH) requirements and
adhere to Good Clinical Practices (GCP) and a central laboratory in Bamako (the capital city of
Mali) where several teams are based. The MRTC infrastructure includes a clinical laboratory
certified by the College of American Pathologists and an equipped insectary, among others. In
addition, the center has 15 other field sites that host epidemiological studies and other collab-
orations with external partners.
From 2003 to 2016, MRTC completed 13 asexual stage vaccine clinical trials and one TBV field
clinical trial evaluating Pfs25H-EPA/Alhydrogel® (Bancoumana, Mali, from 2013 to 2016,
NCT01867463) in collaboration with LMIV at NIH. Field clinical trials of six more candidate
TBVs are ongoing: Pfs25M-EPA/Alhydrogel® and Pfs230D1M-EPA/Alhydrogel®, as well as
the combination of Pfs25M-EPA/Alhydrogel® + Pfs230D1M-EPA/Alhydrogel® (Bethesda, USA
and Bancoumana, Mali; started in 2015, NCT02334462), and Pfs25M-EPA/AS01, Pfs230D1M-
EPA/AS01, and the combination of Pfs25M-EPA/AS01 + Pfs230D1M-EPA/AS01 (Bamako,
Doneguebougou and Bancoumana, Mali; started in 2016, NCT02942277). The success of these
studies depends onMRTC’s technical capacities and strength in community engagement. Dynamic
MRTC teams execute intense programs of volunteer immunization and thorough follow-up
(Figure 4), as well as high-throughput processing of samples in laboratories, rearing of mosquitoes,
mosquito-feeding assays, dissection of mosquitoes, real-time data entry and cleaning, and constant
transportation of persons, samples, and materials between central laboratory and study sites.
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For community engagement, MRTC has built participative, durable, and confidence-based
partnerships with communities at and around the study sites. Initially, community leaders
comprising village heads, elderly, family heads, women’s and youth’s representatives, local
health providers, and school teachers are consulted for permission to build research facilities
and conduct clinical trials in the communities [53] (Figure 4). Subsequently, individual con-
sents are obtained from interested volunteers according to international guidelines.
Local residents are fully involved and meaningfully impacted by the research activities. The
presence of research teams and facilities, along with successful execution of clinical trials, has
contributed to significant improvement of the local healthcare system and even the economy of
the host villages. This positive impact has reinforced community confidence towards clinical
trials and subsequently strengthened community engagement, positioning MRTC to success-
fully conduct TBV field clinical trials in Mali.
10. Bottlenecks and perspectives for TBVs
The future development and potential implementation of current TBV candidates will need to
address important regulatory issues. A major issue involves the conceptual framework for a
Figure 4. General profile of a malaria transmission-blocking vaccine trial in Mali. This is general study process (flow-
chart) followed at the Malaria Research and Training Center (MRTC), Mali in carrying out a malaria vaccine study.
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vaccine that does not directly benefit a recipient, but instead benefits a community only when
the proportion of the population that receives the vaccine achieves the threshold needed to
reduce malaria prevalence and incidence. This threshold may vary between communities
depending on the baseline intensity and ecology of malaria transmission. A TBV can be
considered a “vaccine of solidarity,” whereby the individual accepts vaccination to contribute
to protection of his/her community and thereby ultimately to his/her own benefit. Before any
decision to participate, individuals must balance the risks of immunization and the benefits for
the community and ultimately themselves. To address this issue during clinical trials, candi-
date study participants must pass a test of comprehension that indicates the participant’s
understanding that the TBV has no potential to directly prevent their own infections. At
present, there are few data in the literature on individual and community perceptions and
understanding of TBV. Education on the mechanisms of action and potential community/
individual benefits of TBV will be required before implementation.
Additionally, this community-based approach and vaccine coverage goal sets a high bar to
achieve, even for a malaria vaccine. The vaccine needs to be efficacious not only in children but
also in the majority of individuals in the community that contribute to transmission. The
impact of factors such as malaria exposure, immunodeficiency, coinfection, pregnancy, and
age on antibody responses will require careful study after qualification of promising TBV
candidates. Thus, further research is needed to understand transmission dynamics within a
community, durability and boosting of TBVs, and immunogenicity throughout all individuals
within a community.
Furthermore, the DSF assay that experimentally exposes humans to mosquito bites raises
ethical concerns and logistical burdens that may impact scientific objectives and study designs,
and in some communities, recruitment and retention of volunteers. Mosquitoes used for DSF
are reared in controlled and contained conditions to ensure the safety of the volunteers. While
DSF has approval by ethical review committees, community perceptions should be considered
to reassure participants and promote participant engagement in the process and rationale to
prevent loss to follow-up that can compromise trial objectives. Our experience in Mali shows
that strong community relationships and individual education in study design and goals have
resulted in high participation and retention rates for studies that incorporate DSF assays.
The leading TBV candidates are either not exposed (Pfs25) to the immune system naturally or
induce only modest responses naturally, and thus natural boosting may do little or nothing to
extend antibody responses. Human antibodies should act quickly before degradation in the
mosquito and before parasite traversal of midgut epithelium (~24 h) that limits its accessibility
to antibody. The need for TBV to maintain high levels of potent antibody that preclude
mosquito infection is the major hurdle for developing TBV. Today, several strategies are being
pursued to overcome this hurdle, including the improved adjuvants and delivery systems
discussed above. Additional antigens are also under exploration such as Pfs48/45 [54] and
PfHAP2 [55] that could expand the portfolio of TBV in future.
As there is no existing human-based intervention that uniquely aims at blocking parasite
transmission, such a tool could shift interest toward the interruption of transmission in com-
parison to the urgent need for interventions that protect and treat children under five and
pregnant women. Once TBV tolerability and impact in the field are confirmed in advanced
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clinical trials, consideration must be given for how this vaccine should be implemented along-
side other malaria control tools. Ultimately, TBVs are envisioned as one tool in the toolbox of
interventions, including antimalarial drugs, vector control measures, and other vaccines, that
will be required for malaria elimination.
11. Conclusions
Malaria control has improved with the redoubling of efforts and financial resources in recent
years, but existing tools will lose their effectiveness over time. The best long-term strategy to
address the malaria scourge is its elimination and ultimately eradication, but existing tools are
insufficient for this purpose. This gap has been recognized by the WHO Roadmap for Malaria
Vaccines that specifically calls for vaccines that can be used for elimination [56]. TBVs prevent
human-to-mosquito transfer of parasites and hence are well-suited for use in elimination and
eradication programs. Development of TBV has been hindered by the nature of the target
antigens, which have been difficult to express in proper conformation and are poorly immu-
nogenic, as well as the dearth of resources dedicated to their development. However, increas-
ing attention to elimination by policy makers and funding agencies has reignited interest in
this research area, and improved platforms for vaccine expression and delivery have yielded
promising new TBV candidates that have in some cases advanced to field trials. Collaborative
multidisciplinary teams are now rising to the task of testing TBVs in the field, which also
require specialized facilities to measure transmission-blocking activity of vaccines. Regulatory
issues will need to be addressed as TBVs are developed and implemented, particularly because
these products are designed to benefit the community and not the individual directly. How-
ever, vaccines have been essential for eliminating or eradicating other infectious agents, and
TBVs could be a vital component of a multipronged effort to eradicate malaria from the face of
the earth.
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Acronyms
AnaPN1 Anopheles gambiae aminopeptidase 1
AS01 GSK’s adjuvant system containing liposome, 3-O-desacyl-40-monophosphoryl
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IRB Institutional Review Board
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ITN Insecticide-treated nets
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Malaria Transmission-Blocking Vaccines: Present Status and Future Perspectives
http://dx.doi.org/10.5772/intechopen.77241
377
MRTC Malaria Research and Training Center
NIAID National Institute of Allergy and Infectious Diseases
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RTS,S Hepatitis B surface antigen alone (S) and fused with Plasmodium falciparum
circumsporozoite protein fragment containing its central repeats and T cell
epitopes (RTS)
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SMFA Standard membrane-feeding assay
SOAP Secreted ookinete adhesive protein
SPZ Sporozoite
TBV Transmission-blocking vaccine
TLR4 Toll-like receptor 4
USTTB University of Sciences, Techniques and Technologies of Bamako
VAR2CSA Member of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1)
family binding to chondroitin sulfate A (CSA)
VIMT Vaccine to Interrupt Malaria Transmission
VLP Virus-like particle
WHO World Health Organization
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